Drug Attrition in Check: Shifting Information Input to Where It Matters

|

article image
Expenditures in pharmaceutical R&D are higher than ever, and attrition rates have reached 80-90%. The few compounds that make it to market have to carry the cost of the inefficient development process, but hope lies in improving the data that flows into lead discovery and optimization.

Spotlight

DELO Industrial Adhesives

DELO is a world-leading manufacturer of industrial adhesives, based in Germany. Owner-operated, for over 50 years we have developed tailor-made special adhesives and application technologies for high-tech industries such as automotive, aviation, optoelectronics, and electronics. Through subsidiaries in the US, China, Japan and Singapore, offices in Malaysia, Korea and Taiwan, and partners around the world, we can provide expert help to customers wherever they may be.

OTHER ARTICLES

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 17, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

How pharma can continue engaging HCPs in a world gripped by COVID-19

Article | April 17, 2020

Medscape is the leading source of clinical news, health information, and point-of-care tools for healthcare professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programmes for physicians, nurses, and other healthcare professionals. Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company. Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.

Read More

Comparing HydroxyChloroquine Trials

Article | April 17, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Spotlight

DELO Industrial Adhesives

DELO is a world-leading manufacturer of industrial adhesives, based in Germany. Owner-operated, for over 50 years we have developed tailor-made special adhesives and application technologies for high-tech industries such as automotive, aviation, optoelectronics, and electronics. Through subsidiaries in the US, China, Japan and Singapore, offices in Malaysia, Korea and Taiwan, and partners around the world, we can provide expert help to customers wherever they may be.

Events